Opinion|Videos|September 25, 2024
Optimal Timing and Frequency of Imagining Agents Used in the Detection and Characterization of Oligometastatic Prostate Cancer
Author(s)Jaideep S. Sohi, MD, Jeremie Calais, MD
Jaideep Sohi, MD, and Jeremie Calais, MD, conduct a comparative assessment of gallium-based and non-gallium-based imaging agents for their efficacy in detecting and characterizing oligometastatic prostate cancer.
Advertisement
Video content above is prompted by the following:
- How do you determine the optimal timing and frequency of imaging studies using specific agents to monitor oligometastatic disease progression in prostate cancer patients?
Advertisement
Related to this article
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Magnetic resonance imaging offered a 29 percent higher sensitivity than CT for differentiating liver metastases, but CT provided 12 percent higher sensitivity than MRI for assessing vascular invasion, according to a new 40-study meta-analysis.
In a recent interview with Diagnostic Imaging, Joseph Cavallo, MD, MBA, offered insights on post-deployment monitoring with AI, the potential for improved workflow efficiency and the ongoing challenge of balancing essential clinical skills and AI literacy in the training of radiology residents and fellows.
Does fractional flow reserve (FFR) or quantitative plaque burden from CCTA provide greater prognostic insight into coronary disease?
In the first of a three-part podcast episode, Wendie Berg, MD, PhD, FACR, FSBI, Manisha Bahl, MD, and Amy Patel, MD share insights on the utility of AI in breast imaging with respect to potential advantages, current concerns and future directions.
Catch up on the most-well viewed radiology content in September 2026.
The BiPASS program, which combines 68Ga PSMA PET imaging with prostate MRI prior to the use of prostate biopsy, is slated to be evaluated in an impending phase 3 trial.
For patients with localized prostate cancer, stereotactic body radiotherapy (SBRT) offered comparable freedom from biochemical/clinical failure at eight years and nearly 40 percent lower urinary incontinence in comparison to radical prostatectomy, according to research presented at the ASTRO conference.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
Emerging Research Insights and New Advances in Neuroradiology
2
MRI, CT or Ultrasound: Which Modality Offers the Most Utility for Imaging of Pancreatic Cancer?
3
FDA Grants Fast Track Designation for Pre-Biopsy Use of PSMA PET and MRI for Prostate Cancer Detection
4
ASTRO: What New Phase 3 Research Reveals About SBRT for Patients with Localized Prostate Cancer
5